Wird geladen...
Monalizumab: inhibiting the novel immune checkpoint NKG2A
The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now treated with immune system targeting antibodies to PD-1, PD-L1 and CTLA-4, alleviating inhi...
Gespeichert in:
| Veröffentlicht in: | J Immunother Cancer |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2019
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6798508/ https://ncbi.nlm.nih.gov/pubmed/31623687 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-019-0761-3 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|